logo
Ptil Tekhelet Educational Center: Israel's newest, bluest cultural venue

Ptil Tekhelet Educational Center: Israel's newest, bluest cultural venue

Yahoo14-07-2025
'The main takeaway from The Tekhelet Educational Center is the deep appreciation for a beautiful mitzvah.' 
You could say that Baruch Sterman has a case of the 'blues.'
The doctor of physics, who worked as a hi-tech entrepreneur and technologist, founded Ptil Tekhelet – the Israel-based nonprofit Association for the Promotion and Distribution of Tekhelet – to help provide the blue dye described in the Torah for anybody who wants it. In 2012, he and wife, Judy, published The Rarest Blue. The book, which has sold more than 10,000 copies, details the search through centuries for the mysterious blue dye.
Sterman's latest endeavor is the Tekhelet Educational Center in Kfar Adumim, near Jericho. The center features interactive exhibitions and activities, bringing the world of tekhelet to light through fascinating displays, videos, and active participation. At the center, visitors can explore the displays in the discovery room, enjoy multi-media presentations on the history and making of tekhelet, and actually experience the process of dying with it.
'The whole story of tekhelet brings together Jewish culture, history, archaeology, chemistry and, of course, Torah,' Sterman says.
'Discovering tekhelet and wearing it was not a possibility 40 or 45 years ago,' he says. 'There was no tekhelet except for one small sect of Hassidim, the Radzyn, who thought their rebbe had discovered it. Tekhelet had disappeared 1,300 years ago in 650 CE.'
People didn't wear colored clothing in ancient times, the tekhelet expert explains. 'The colors were mostly neutrals. Here and there, flowers and berries were used to color clothes – but even still, the dyes were earth tones.'
Sterman says the snail, discovered 4,000 years ago, brought a new dye and extremely vibrant blue or purple colors that didn't fade. These colors – tekhelet (blue) and argaman (purple) – became a trend in the ancient Mediterranean fashion world. The dye was worth more than 20 times its weight in gold.
'Those who could afford it were called 'the purple people,'' he says. 'The traders were called porphyra, the Greek name of the murex snail, aka hilazon [in Hebrew], and also of the dye. It is also the core of the name Phoenicia, which means 'the people who deal with purple.''
The Phoenicians went all over the Mediterranean searching for snails and making a lot of money. In the Tanach, they are closely associated with tekhelet and argaman. Both the dye and the clothing were traded throughout the world – as far as Persia. When the Mediterranean was captured by the Romans, they took over the business. When Alexander the Great raided Cyrus's tomb, he found items dyed purple and blue, Sterman says.
Roman emperors coveted the rich colors, and royalty became associated as being 'born into the purple.' Purple and blue became associated with the royal house. That was the downfall of tekhelet, Sterman explains.
But for Jews, tekhelet was much more than a fashion statement.
'While Roman kings and princes all wore tekhelet, when the Torah says, 'Put it on your clothes,' it is reminding us that every single Jew is a king [because] he is a representative of the King of Kings,' Sterman says. 'The Jewish religion is democratic, but it equalizes by elevating. Even the lowest people in society are elevated to the level of king and prince. The Jew has a mission: to save the world. When he looks at the tekhelet, he is being given a mission to remember all of the mitzvot and remember his personal responsibility and goal in life,' Sterman explains.
'When the Romans got their greedy little hands on the purple dying industry, it became much more expensive and harder to get,' Sterman continues. 'They passed laws saying that having tekhelet in your home is a crime against the emperor. Romans and Jews developed a smuggling network for the dye, and it became very difficult to obtain. That is when more and more people began wearing white tzitzit. Only the most devout, richest Jews had the guts to wear tekhelet.'
The art of tekhelet was lost in the giant war of the 7th century between Byzantine Romans, Sasanian Persians, and the emerging Muslims, known as the Byzantine-Sasanian War of 602-628: the Last Great War of Antiquity. 'During the Dark Ages, dye houses along the Mediterranean were destroyed, and all the knowledge of identification and tekhelet production became obsolete,' Sterman says.
While the Talmud, as well as Greek and Roman authors, wrote about tekhelet, it became very complicated to decipher what they wrote and understand exactly what the porphyra or the hilazon actually were. Two hundred years ago, archaeological and excavation finds were discovered. Scholars studied ancient languages, like Akkadian, and were learning more about chemistry, chipping away at the wall of obscurity of the ancient world.
At the beginning of the 1800s, there was a lot of archeology research being done throughout the Middle East, and the British and French began finding treasures of the ancient world. At the same time, the world was discovering synthetic dyes.
'This was not lost on the Jews,' Sterman says. 'There were rabbis trying to find out what these ancient dyes were. Most notable among them was Rabbi Gershon Henoch Leiner from Radzyn [a town in eastern Poland]. His grandfather was the Ishbitzer Rebbe (the Mei Shiloah), who studied under the Kotzker Rebbe. Rabbi Gershon went to Italy, which had opened its first public aquarium in Naples in the 1800s, searching for the hilazon.'
Secular scientists were also studying snails, honing in on specific sea snails in the murex family, says the Ptil Tekhelet founder. 'They knew these snails could make dyes. Chemists were analyzing them, and they were finding piles of ancient snail shells in Tyre, Turkey, Cyprus, Greece, Morocco, Tunisia/Carthage, and Italy.'
But what did these large piles of snail shells mean?
Sterman explains, 'A few piles of shells probably indicated it was somebody's supper. But a lot of snails? That's a production facility.'
As scientists began experimenting with the dye, they were able to make the purple argaman color.
The problem is that the chemists were only able to obtain a purple dye from the murex snails; but according to the Torah, tekhelet is supposed to remind us of the sea or the sky – so it was blue, not purple.
Rabbi Yitzhak Halevi Herzog, the first chief rabbi of the State of Israel and grandfather of President Isaac Herzog, wrote a doctorate in 1914 on tekhelet at the University of London. Besides speaking 12 languages, the distinguished scholar coined the phrase 'Hebrew porphyrology,' based on the above-mentioned Greek name of the murex/hilazon snail.
Unfortunately, he wasn't able to get past the purple; the trail went cold.
In 1985, Prof. Otto Elsner working at Shenkar College of Fibers in Herzliya made an accidental discovery. He was researching properties of the dyes that came out of the snail and noticed that at very specific times in the dying process, if you expose the dye to sunlight, it turns blue, not purple.
Although Elsner wasn't interested in tekhelet, his research was picked up by Rabbi Eliyahu Tavger, who began the process of making the ritual blue dye. While looking for scuba divers to help him find the mysterious snails, he met Sterman and dentist Ari Greenspan. The two went diving off the northern coast of Israel and found plenty of murex snails. As it turns out, the snails abound all over the Mediterranean.
Sterman joined with Tavger and formed the Ptil Tekhelet nonprofit organization.
With catering options and a large picnic area that can accommodate up to 100 guests, the Tekhelet Educational Center in Kfar Adumim is not only educational but has become an ideal place to celebrate bar mitzvah and hanahat tefillin ceremonies, where a 13-year-old boy comes of age and puts on tefillin for the first time.
'We had such an amazing, meaningful experience at Ptil Tekhelet today!' one patron wrote enthusiastically after celebrating his son's tefillin-laying ceremony. 'The guide was so knowledgeable, and his passion really came through. The icing on the cake was the [tekhelet-making] demo at the end. The entire group was in absolute amazement, seeing the process happen. I think this place is a must-visit for every religious boy.'
Sterman concludes, 'The main takeaway from The Tekhelet Educational Center is the deep appreciation for a beautiful mitzvah.' 
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Israeli hospital to join NASA, SpaceX mission to study microgravity's effects on diseases
Israeli hospital to join NASA, SpaceX mission to study microgravity's effects on diseases

Yahoo

timea day ago

  • Yahoo

Israeli hospital to join NASA, SpaceX mission to study microgravity's effects on diseases

For this experiment, Sheba will partner with the US firm SpaceTango to grow several bacterial species aboard the ISS using a specially designed Earth-controlled system. Sheba Medical Center's ARC Digital Innovation Center is joining a NASA and SpaceX mission to the International Space Station (ISS) on Thursday for a study on the extreme conditions of space, Sheba announced on Wednesday. The experiment, dubbed the ARC Space Lab, is the second of its kind from Sheba, which remains the only hospital in Israel carrying out studies in space. How does microgravity impact diseases? One of the major barriers facing humankind's continued expansion into outer space is the unknown effects of long-term space travel on the human body. Finding out how to help astronauts adapt to challenges they may face when off planet for extended periods of time is a natural and essential step forward for medical science. For this experiment, Sheba will partner with the US firm SpaceTango to grow several bacterial species aboard the ISS using a specially designed Earth-controlled system. After growth under microgravity, the bacteria will be stabilized, frozen at -80°C and returned to Earth for molecular and transcriptional analysis and direct comparison to bacteria grown simultaneously in an identical lab setup on Earth. It is known that space has an impact on bacteria. For example, astronauts are more likely to develop infections, theorized to be due to a combination of microgravity, radiation, stress, and changes in the human microbiome. However, this goes both ways. In a previous ARC Space Lab study, it was found that bacteria in space are less likely to develop antibiotic resistance. This was a major discovery and went against the prevailing hypotheses of the time, and the findings of this study were published in the peer-reviewed academic journal Microbiology Spectrum. 'We know that space conditions affect bacterial behavior, including how they grow, express genes, and acquire traits like antibiotic resistance or virulence,' Sheba Infectious Diseases Unit head Prof. Ohad Gal-Mor said in a statement. 'This experiment will allow us, for the first time, to systematically and molecularly map how the genetic expression profile of several pathogenic bacteria changes in space. The insights we gain will augment our understanding of infectious disease risks in space travel, and also expand our knowledge of gene regulation and bacterial physiology in general.' Sheba ARC director Prof. Eyal Zimlichman added, 'To understand the limits of medicine, we sometimes need to go beyond the limits of Earth. Our experiment in space examines how bacterial behavior changes under extreme conditions and what that means for human health—not just for astronauts, but also here on Earth. This is part of ARC's mission to shape the future of medicine, wherever it's needed.' Solve the daily Crossword

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone
Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Yahoo

timea day ago

  • Yahoo

Pancreatic Cancer Phase 2a Study with Can-Fite's Namodenoson Achieved Over 50% Enrollment Milestone

Primary endpoint is safety; Namodenoson continues to demonstrate a favorable safety profile Ramat Gan, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molecule drugs for the treatment of cancer and inflammatory diseases, today announced that it achieved the over 50% enrollment milestone in its Phase 2a trial of Namodenoson for pancreatic cancer. The Phase 2a study is a multicenter, open-label trial enrolling patients with advanced pancreatic adenocarcinoma whose disease has progressed following at least one line of prior therapy. The study is evaluating the safety (primary endpoint), clinical activity, and pharmacokinetics (PK) of Namodenoson in this patient population. Participants receive oral Namodenoson at a dose of 25 mg, administered twice daily in continuous 28-day cycles. Patients are regularly monitored for safety, and to date, Namodenoson has demonstrated a favorable safety profile. The study is led by Prof. Salomon Stemmer, a renowned oncologist and key opinion leader at the Davidoff Center, Rabin Medical Center, Israel. 'This milestone reflects the strong interest among both investigators and patients in exploring Namodenoson as a potential treatment for one of the deadliest and most aggressive cancers,' stated Pnina Fishman, Ph.D., Chief Scientific Officer of Can-Fite BioPharma. 'We are encouraged by the pace of enrollment and remain committed to advancing Namodenoson as a much-needed therapeutic option for patients with pancreatic cancer.' Namodenoson is a highly selective A3 adenosine receptor (A3AR) agonist, which has shown a compelling safety profile and demonstrated anti-tumor activity in preclinical pancreatic cancer models. The drug is also being evaluated in clinical trials for advanced liver cancer. Namodenoson has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. About Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase 3 trial for psoriasis and commenced a pivotal Phase 3 trial. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: Forward-Looking Statements This press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are 'forward looking statements'. Forward-looking statements can be identified by the use of forward-looking words such as 'believe,' 'expect,' 'intend,' 'plan,' 'may,' 'should' or 'anticipate' or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. For example, the Company is using forward-looking statements when it discusses the completion of the offerings, the satisfaction of customary closing conditions related to the offerings and the intended use of proceeds therefrom. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our market and other conditions, history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the 'Risk Factors' section of Can-Fite's Annual Report on Form 20-F filed with the SEC on April 14, 2025 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. Contact Can-Fite BioPharma Motti Farbstein info@ +972-3-9241114

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

Yahoo

timea day ago

  • Yahoo

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) ('Clearmind') has led to the filing of a new international patent application under the Patent Cooperation Treaty. The application covers its innovative combination therapy of 5-methoxy-2-aminoindane and N-Acylethanolamines (MEAI) and Palmitoylethanolamide (PEA). This proprietary combination is designed to address two significant global health challenges: obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). According to the World Health Organization, obesity affects over 890 million people worldwide and is a leading risk factor for a range of chronic conditions. Meanwhile, non-alcoholic fatty liver disease (NAFLD), which is closely linked to metabolic disorders and poor long-term outcomes, is estimated to impact more than 30% of the global adult population, according to the article titled 'Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons,' published in August 2023. Despite the scale of these problems, treatment options remain limited. According to Clearmind, the novel approach has the potential to offer a safe and effective therapeutic alternative, leveraging the unique pharmacological profile of MEAI alongside the anti-inflammatory and neuroprotective properties of PEA. This latest development adds to multiple patent applications already filed in the U.S. and other countries as part of the ongoing SciSparc-Clearmind collaboration. About SciSparc Ltd. (Nasdaq: SPRC): SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive cannabidiol: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; and SCI-210 for the treatment of autism and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds' oil-based products on the Marketplace. About Clearmind Medicine Inc. (Nasdaq: CMND) (FSE: CWY) Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements. Clearmind's intellectual portfolio currently consists of 19 patent families including 31 granted patents. For further information visit: Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward looking statements when discussing the potential benefits and advantages of the new patent application, that this proprietary combination is designed to address two significant global health challenges: obesity and MASLD, and that it has the potential to offer a safe and effective therapeutic alternative, leveraging the unique pharmacological profile of MEAI alongside the anti-inflammatory and neuroprotective properties of PEA. Since such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (the 'SEC') on April 24, 2025, and in subsequent filings with the SEC. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Investor Contact:IR@ +972-3-6167055Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store